Apo2L/TRAIL triggers apoptosis by binding to functional death receptors (DR4 and DR5)17, 18, but, regardless of the fact that these receptors are highly expressed in HNSCC lines, many tumor cell lines end up showing resistance to treatment with TRAIL monotherapy18, 19. This evidence concerns the gene TNFRSF10B and neoplasm.